Online inquiry

IVTScrip™ mRNA-Anti-MS4A1, SCT-400(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ14678MR)

This product GTTS-WQ14678MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & 5-Methyl-CTP & Pseudo-UTP. It ecodes the monoclonal antibody that targets MS4A1 gene. The antibody can be applied in B cell lymphoma research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP & Pseudo-UTP
5' Cap Cap 1
Species Chimeric
RefSeq NM_001048028.1
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 485430
UniProt ID Q3C2E2
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-MS4A1, SCT-400(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) (GTTS-WQ14678MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ3945MR IVTScrip™ mRNA-Anti-CTLA4, BCD-145(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA BCD-145
GTTS-WQ9282MR IVTScrip™ mRNA-Anti-TACSTD2, IMMU-132(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA IMMU-132
GTTS-WQ13766MR IVTScrip™ mRNA-Anti-MSTN, REGN-1033(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA REGN-1033
GTTS-WQ12779MR IVTScrip™ mRNA-Anti-NOTCH2&NOTCH3, OMP-59R5(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA OMP-59R5
GTTS-WQ1030MR IVTScrip™ mRNA-Anti-MET, ABBV-399(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA ABBV-399
GTTS-WQ12170MR IVTScrip™ mRNA-Anti-MSLN, MORAb-009(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA MORAb-009
GTTS-WQ15092MR IVTScrip™ mRNA-Anti-TNC, ST2146(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA ST2146
GTTS-WQ14288MR IVTScrip™ mRNA-Anti-CSF1R, RG7155(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA RG7155
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW